SUPPLEMENTARY DATA

Supplementary Figure 1a. Predicted 3-year probabilities of progressing to DM in all DPP participants regardless of adherence by quartile of risk of developing DM if participants had been assigned to the placebo intervention



Supplementary Figure 1b. Predicted 3-year probabilities of regressing to NGR in all DPP participants regardless of adherence by quartile of risk of developing DM if participants had been assigned to the placebo intervention



©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

Supplementary Table 1. Multivariable models predicting progression to diabetes for the entire DPP randomized population regardless of adherence

	Hazard ratio (95% CI)		
Baseline Predictors	**Lifestyle**	**Metformin**	**Placebo**
Age		1.014 (1.000 ,1.027)	
Sex and GDM status			
Female with no history of pregnancy vs. male			0.721 (0.443 ,1.172)
Female with history of pregnancy but no GDM vs. male			1.047 (0.794 ,1.380)
Female with history of GDM vs. male			1.538 (1.071 ,2.209)
College graduate vs. non-college graduate			1.315 (1.043 ,1.659)
Current smoking: Yes vs. No		1.585 (1.004 ,2.501)	
Physical activity more than 150 mins/week: Yes vs. No	1.293 (0.930 ,1.797)		
Polycystic ovarian disease: Yes vs. No		1.784 (0.875 ,3.637)	
Family history of diabetes: Yes vs. No		1.299 (0.960 ,1.757)	
BMI (kg/m^2)	1.052 (1.031 ,1.073)		1.020 (1.004 ,1.037)
Systolic blood pressure (mm Hg)			1.008 (0.999 ,1.016)
Fasting glucose (mg/dL)	1.072 (1.052 ,1.092)	1.059 (1.044 ,1.075)	1.089 (1.076 ,1.103)
Natural log-transformed triglyceride (mg/dL)	1.459 (1.075 ,1.979)	1.631 (1.245 ,2.135)	1.275 (1.006 ,1.617)
C-index	0.593	0.633	0.544
Calibration p-value for decile categories at year 3	0.391	0.231	0.392

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

Supplementary Table 2. Formula for calculating probability of progression to DM at 3 years in the entire randomized DPP population regardless of adherence

Formulas	Probability(progression to DM) = 1- $S_0^{\exp(F(X))}$	
Treatment	S_0	F(X)
Lifestyle	0.893	0.051×(BMI-34)+0.069×(fasting glucose-107)+0.378×(log(triglyceride)-5)+0.257×PA
Metformin	0.840	0.014×(Age-51)+0.261×FH+0.057×(fasting glucose-107)+0.489×(log(triglyceride)-5)+0.461×SM+0.579×polycystic
Placebo	0.791	-0.328×FNP+0.046×FP+0.431×GDM+0.020×(BMI−34)+0.086×(fasting glucose-107)+0.008×(SBP-124)+0.243x(log(triglyceride)-5)+0.274×CG

PA=1 if physical activity more than 150 min/wk; 0 otherwise
FH =1 if a subject has family history of diabetes; 0 otherwise
Polycystic =1 if a subject is female and has polycystic syndrome; 0 otherwise
SM=1 if a subject is a current smoker; 0 otherwise
CG=1 if a subject is a college graduate; 0 otherwise
FNP=1 if a subject is female and has never been pregnant; 0 otherwise
FP=1 if a subject is female and has been pregnant but no history of GDM; 0 otherwise
GDM=1 if a subject is female and has had GDM; 0 otherwise
S_0: three-year survival probability for a participant with reference covariate pattern (continuous covariates equal the sample average and categorical covariates equal male or no)

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

TRIPOD checklist

Section/Topic	Item		Checklist Item	Page
Title and abstract				
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	3-4
Introduction				
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	5-6
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	6-7
Methods				
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	Done
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Done
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Done
	5b	D;V	Describe eligibility criteria for participants.	Done
	5c	D;V	Give details of treatments received, if relevant.	Done
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Done
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	
Predictors	7a	D;V	Clearly define all predictors used in developing the multivariable prediction model, including how and when they were measured.	Done
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	8
Sample size	8	D;V	Explain how the study size was arrived at.	n/a
Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Done
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	Done
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Done
	10c	V	For validation, describe how the predictions were calculated.	n/a
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Done
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	n/a
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	n/a
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	n/a
Results				
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	13
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	13-14
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	n/a
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	14
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	Table 2 (15)
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	16-17 (Table 3)
	15b	D	Explain how to use the prediction model.	16-18
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	18-19
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	n/a
Discussion				
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	22-23
Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	n/a

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	19-22
Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	20-22
Other information				
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	10
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	7, 24

*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

DPP Research Group Investigators

Pennington Biomedical Research Center (Baton Rouge, LA)
George A. Bray, MD*
Iris W. Culbert, BSN, RN, CCRC**
Catherine M. Champagne, PhD, RD
Barbara Eberhardt, RD, LDN
Frank Greenway, MD
Fonda G. Guillory, LPN
April A. Herbert, RD
Michael L. Jeffirs, LPN
Betty M. Kennedy, MPA
Jennifer C. Lovejoy, PhD
Laura H. Morris, BS
Lee E. Melancon, BA, BS
Donna Ryan, MD
Deborah A. Sanford, LPN
Kenneth G. Smith, BS, MT
Lisa L. Smith, BS
Julia A. St.Amant, RTR
Richard T. Tulley, PhD
Paula C. Vicknair, MS, RD
Donald Williamson, PhD
Jeffery J. Zachwieja, PhD

***University of Chicago* (Chicago, IL)**
Kenneth S. Polonsky, MD*
Janet Tobian, MD, PhD*
David Ehrmann, MD*
Margaret J. Matulik, RN, BSN**
Bart Clark, MD
Kirsten Czech, MS
Catherine DeSandre, BA
Ruthanne Hilbrich, RD
Wylie McNabb, EdD
Ann R. Semenske, MS, RD

***Jefferson Medical College* (Philadelphia, PA)**
Jose F. Caro, MD*
Pamela G. Watson, RN, ScD*
Barry J. Goldstein, MD, PhD*
Kellie A. Smith, RN, MSN**
Jewel Mendoza, RN, BSN**
Renee Liberoni, MPH
Constance Pepe, MS, RD
John Spandorfer, MD

***University of Miami* (Miami, FL)**
Richard P. Donahue, PhD*
Ronald B. Goldberg, MD*
Ronald Prineas, MD, PhD*
Patricia Rowe, MPA**
Jeanette Calles, MSEd
Paul Cassanova-Romero, MD
Hermes J. Florez, MD
Anna Giannella, RD, MS
Lascelles Kirby, MS
Carmen Larreal
Valerie McLymont, RN
Jadell Mendez
Juliet Ojito, RN
Arlette Perry, PhD
Patrice Saab, PhD

***The University of Texas Health Science Center* (San Antonio, TX)**
Steven M. Haffner, MD, MPH*
Maria G. Montez, RN, MSHP, CDE**
Carlos Lorenzo, MD, PhD
Arlene Martinez, RN, BSN, CDE

***University of Colorado* (Denver, CO)**
Richard F. Hamman, MD, DrPH*
Patricia V. Nash, MS**
Lisa Testaverde, MS**
Denise R. Anderson, RN, BSN
Larry B. Ballonoff, MD
Alexis Bouffard, MA,
B. Ned Calonge, MD, MPH
Lynne Delve
Martha Farago, RN
James O. Hill, PhD
Shelley R. Hoyer, BS
Bonnie T. Jortberg, MS, RD, CDE
Dione Lenz, RN, BSN
Marsha Miller, MS, RD
David W. Price, MD
Judith G. Regensteiner, PhD
Helen Seagle, MS, RD
Carissa M. Smith, BS
Sheila C. Steinke, MS
Brent VanDorsten, PhD

***Joslin Diabetes Center* (Boston, MA)**
Edward S. Horton, MD*
Kathleen E. Lawton, RN**
Ronald A. Arky, MD
Marybeth Bryant
Jacqueline P. Burke, BSN
Enrique Caballero, MD
Karen M. Callaphan, BA
Om P. Ganda, MD
Therese Franklin
Sharon D. Jackson, MS, RD, CDE
Alan M. Jacobsen, MD
Lyn M. Kula, RD
Margaret Kocal, RN, CDE

* denotes Principal Investigator
** denotes Program Coordinator

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

DPP Research Group Investigators

Maureen A. Malloy, BS
Maryanne Nicosia, MS, RD
Cathryn F. Oldmixon, RN
Jocelyn Pan, BS, MPH
Marizel Quitingon
Stacy Rubtchinsky, BS
Ellen W. Seely, MD
Dana Schweizer, BSN
Donald Simonson, MD
Fannie Smith, MD
Caren G. Solomon, MD, MPH
James Warram, MD

***VA Puget Sound Health Care System and University of Washington* (Seattle, WA)**

Steven E. Kahn, MB, ChB*
Brenda K. Montgomery, RN, BSN, CDE**
Wilfred Fujimoto, MD
Robert H. Knopp, MD
Edward W. Lipkin, MD
Michelle Marr, BA
Dace Trence, MD

***University of Tennessee* (Memphis, TN)**

Abbas E. Kitabchi, PhD, MD, FACP*
Mary E. Murphy, RN, MS, CDE, MBA**
William B. Applegate, MD, MPH
Michael Bryer-Ash, MD
Sandra L. Frieson, RN
Raed Imseis, MD
Helen Lambeth, RN, BSN
Lynne C. Lichtermann, RN, BSN
Hooman Oktaei, MD
Lily M.K. Rutledge, RN, BSN
Amy R. Sherman, RD, LD
Clara M. Smith, RD, MHP, LDN
Judith E. Soberman, MD
Beverly Williams-Cleaves, MD

***Northwestern University's Feinberg School of Medicine* (Chicago, IL)**

Boyd E. Metzger, MD*
Mariana K. Johnson, MS, RN**
Catherine Behrends
Michelle Cook, MS
Marian Fitzgibbon, PhD
Mimi M. Giles, MS, RD
Deloris Heard, MA
Cheryl K.H. Johnson, MS, RN
Diane Larsen, BS
Anne Lowe, BS
Megan Lyman, BS
David McPherson, MD
Mark E. Molitch, MD
Thomas Pitts, MD
Renee Reinhart, RN, MS
Susan Roston, RN, RD
Pamela A. Schinleber, RN, MS

***Massachusetts General Hospital* (Boston, MA)**

David M. Nathan, MD*
Charles McKitrick, BSN**
Heather Turgeon, BSN**
Kathy Abbott
Ellen Anderson, MS, RD
Laurie Bissett, MS, RD
Enrico Cagliero, MD
Jose C. Florez, MD, PhD+
Linda Delahanty, MS, RD
Valerie Goldman, MS, RD
Alexandra Poulos

***University of California-San Diego* (La Jolla, CA)**

Jerrold M. Olefsky, MD*
Mary Lou Carrion-Petersen, RN, BSN**
Elizabeth Barrett-Connor, MD
Steven V. Edelman, MD
Robert R. Henry, MD
Javiva Horne, RD
Simona Szerdi Janesch, BA
Diana Leos, RN, BSN
Sundar Mudaliar, MD
William Polonsky, PhD
Jean Smith, RN
Karen Vejvoda, RN, BSN, CDE, CCRC

***St. Luke's-Roosevelt Hospital* (New York, NY)**

F. Xavier Pi-Sunyer, MD*
Jane E. Lee, MS**
David B. Allison, PhD
Nancy J. Aronoff, MS, RD
Jill P. Crandall, MD
Sandra T. Foo, MD
Carmen Pal, MD
Kathy Parkes, RN
Mary Beth Pena, RN
Ellen S. Rooney, BA
Gretchen E.H. Van Wye, MA
Kristine A. Viscovich, ANP

***Indiana University* (Indianapolis, IN)**

David G. Marrero, PhD*
Melvin J. Prince, MD*
Susie M. Kelly, RN, CDE**
Yolanda F. Dotson, BS
Edwin S. Fineberg, MD
John C. Guare, PhD

* denotes Principal Investigator
** denotes Program Coordinator

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

DPP Research Group Investigators

Angela M. Hadden
James M. Ignaut, MA
Marcia L. Jackson
Marian S. Kirkman, MD
Kieren J. Mather, MD
Beverly D. Porter, MSN
Paris J. Roach, MD
Nancy D. Rowland, BS, MS
Madelyn L. Wheeler, RD

Medstar Research Institute **(Washington, DC)**

Robert E. Ratner, MD*
Gretchen Youssef, RD, CDE**
Sue Shapiro, RN, BSN, CCRC**
Catherine Bavido-Arrage, MS, RD, LD
Geraldine Boggs, MSN, RN
Marjorie Bronsord, MS, RD, CDE
Ernestine Brown
Wayman W. Cheatham, MD
Susan Cola
Cindy Evans
Peggy Gibbs
Tracy Kellum, MS, RD, CDE
Claresa Levatan, MD
Asha K. Nair, BS
Maureen Passaro, MD
Gabriel Uwaifo, MD

University of Southern California/UCLA Research Center **(Alhambra, CA)**

Mohammed F. Saad, MD*
Maria Budget**
Sujata Jinagouda, MD**
Khan Akbar, MD
Claudia Conzues
Perpetua Magpuri
Kathy Ngo
Amer Rassam, MD
Debra Waters
Kathy Xapthalamous

Washington University **(St. Louis, MO)**

Julio V. Santiago, MD* (deceased)
Samuel Dagogo-Jack, MD, MSc, FRCP, FACP*
Neil H. White, MD, CDE*
Samia Das, MS, MBA, RD, LD**
Ana Santiago, RD**
Angela Brown, MD
Edwin Fisher, PhD
Emma Hurt, RN
Tracy Jones, RN
Michelle Kerr, RD
Lucy Ryder, RN
Cormarie Wernimont, MS, RD

Johns Hopkins School of Medicine **(Baltimore, MD)**

Christopher D. Saudek, MD*
Vanessa Bradley, BA**
Emily Sullivan, MEd, RN**
Tracy Whittington, BS**
Caroline Abbas
Frederick L. Brancati, MD, MHS
Jeanne M. Clark, MD
Jeanne B. Charleston, RN, MSN
Janice Freel
Katherine Horak, RD
Dawn Jiggetts
Deloris Johnson
Hope Joseph
Kimberly Loman
Henry Mosley
Richard R. Rubin, PhD
Alafia Samuels, MD
Kerry J. Stewart, EdD
Paula Williamson

University of New Mexico **(Albuquerque, NM)**

David S. Schade, MD*
Karwyn S. Adams, RN, MSN**
Carolyn Johannes, RN, CDE**
Leslie F. Atler, PhD
Patrick J. Boyle, MD
Mark R. Burge, MD
Janene L. Canady, RN, CDE
Lisa Chai, RN
Ysela Gonzales, RN, MSN
Doris A. Hernandez-McGinnis
Patricia Katz, LPN
Carolyn King
Amer Rassam, MD
Sofya Rubinchik, MD
Willette Senter, RD
Debra Waters, PhD

Albert Einstein College of Medicine **(Bronx, NY)**

Harry Shamoon, MD*
Janet O. Brown, RN, MPH, MSN**
Elsie Adorno, BS
Liane Cox, MS, RD
Jill Crandall, MD
Helena Duffy, MS, C-ANP
Samuel Engel, MD
Allison Friedler, BS
Crystal J. Howard-Century, MA
Stacey Kloiber, RN

* denotes Principal Investigator
** denotes Program Coordinator

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

DPP Research Group Investigators

Nadege Longchamp, LPN
Helen Martinez, RN, MSN, FNP-C
Dorothy Pompi, BA
Jonathan Scheindlin, MD
Elissa Violino, RD, MS
Elizabeth Walker, RN, DNSc, CDE
Judith Wylie-Rosett, EdD, RD
Elise Zimmerman, RD, MS
Joel Zonszein, MD

***University of Pittsburgh* (Pittsburgh, PA)**

Trevor Orchard, MD*
Rena R. Wing, PhD*
Gaye Koenning, MS, RD**
M. Kaye Kramer, BSN, MPH**
Susan Barr, BS
Miriam Boraz
Lisa Clifford, BS
Rebecca Culyba, BS
Marlene Frazier
Ryan Gilligan, BS
Susan Harrier, MLT
Louann Harris, RN
Susan Jeffries, RN, MSN
Andrea Kriska, PhD
Qurashia Manjoo, MD
Monica Mullen, MHP, RD
Alicia Noel, BS
Amy Otto, PhD
Linda Semler, MS, RD
Cheryl F. Smith, PhD
Marie Smith, RN, BSN
Elizabeth Venditti, PhD
Valarie Weinzierl, BS
Katherine V. Williams, MD, MPH
Tara Wilson, BA

***University of Hawaii* (Honolulu, HI)**

Richard F. Arakaki, MD*
Renee W. Latimer, BSN, MPH**
Narleen K. Baker-Ladao, BS
Ralph Beddow, MD
Lorna Dias, AA
Jillian Inouye, RN, PhD
Marjorie K. Mau, MD
Kathy Mikami, BS, RD
Pharis Mohideen, MD
Sharon K. Odom, RD, MPH
Raynette U. Perry, AA

***Southwest American Indian Centers* (Phoenix, AZ; Shiprock, NM; Zuni, NM)**

William C. Knowler, MD, DrPH*+
Norman Cooeyate**
Mary A. Hoskin, RD, MS**
Carol A. Percy, RN, MS**
Kelly J. Acton, MD, MPH
Vickie L. Andre, RN, FNP
Rosalyn Barber
Shandiin Begay, MPH
Peter H. Bennett, MB, FRCP
Mary Beth Benson, RN, BSN
Evelyn C. Bird, RD, MPH
Brenda A. Broussard, RD, MPH, MBA, CDE
Marcella Chavez, RN, AS
Tara Dacawyma
Matthew S. Doughty, MD
Roberta Duncan, RD
Cyndy Edgerton, RD
Jacqueline M. Ghahate
Justin Glass, MD
Martia Glass, MD
Dorothy Gohdes, MD
Wendy Grant, MD
Robert L. Hanson, MD, MPH
Ellie Horse
Louise E. Ingraham, MS, RD, LN
Merry Jackson
Priscilla Jay
Roylen S. Kaskalla
David Kessler, MD
Kathleen M. Kobus, RNC-ANP
Jonathan Krakoff, MD
Catherine Manus, LPN
Sara Michaels, MD
Tina Morgan
Yolanda Nashboo (deceased)
Julie A. Nelson, RD
Steven Poirier, MD
Evette Polczynski, MD
Mike Reidy, MD
Jeanine Roumain, MD, MPH
Debra Rowse, MD
Sandra Sangster
Janet Sewenemewa
Darryl Tonemah, PhD
Charlton Wilson, MD
Michelle Yazzie

***George Washington University Biostatistics Center* (DPP Coordinating Center Rockville, MD)**

Raymond Bain, PhD*
Sarah Fowler, PhD*

* denotes Principal Investigator
** denotes Program Coordinator

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1

SUPPLEMENTARY DATA

DPP Research Group Investigators

Tina Brenneman**
Solome Abebe
Julie Bamdad, MS
Jackie Callaghan
Sharon L. Edelstein, ScM
Mary Foulkes, PhD
Yuping Gao
Kristina L. Grimes
Nisha Grover
Lori Haffner, MS
Steve Jones
Tara L. Jones
Richard Katz, MD
John M. Lachin, ScD
Pamela Mucik
Robert Orlosky
James Rochon, PhD
Alla Sapozhnikova
Hanna Sherif, MS
Charlotte Stimpson
Marinella Temprosa, PhD
Fredricka Walker-Murray

Central Biochemistry Laboratory **(Seattle, WA)**
Santica Marcovina, PhD, ScD*
Greg Strylewicz, PhD**
F. Alan Aldrich

Carotid Ultrasound
Dan O'Leary, MD*

CT Scan Reading Center
Elizabeth Stamm, MD*

Epidemiological Cardiology Research Center-Epicare **(Winston-Salem, NC)**
Pentti Rautaharju, MD, PhD*
Ronald J. Prineas, MD, PhD*/*
Teresa Alexander
Charles Campbell, MS
Sharon Hall
Yabing Li, MD
Margaret Mills
Nancy Pemberton, MS
Farida Rautaharju, PhD
Zhuming Zhang, MD

Nutrition Coding Center **(Columbia, SC)**
Elizabeth Mayer-Davis, PhD*
Robert R. Moran, PhD**

Quality of Well-Being Center **(La Jolla, CA)**
Ted Ganiats, MD*
Kristin David, MHP*
Andrew J. Sarkin, PhD*
Erik Groessl, PhD

NIH/NIDDK **(Bethesda, MD)**
R. Eastman, MD
Judith Fradkin, MD
Sanford Garfield, PhD

Centers for Disease Control & Prevention **(Atlanta, GA)**
Edward Gregg, PhD
Ping Zhang, PhD

University of Michigan **(Ann Arbor, MI)**
William H. Herman, MD, MPH

†Genetics Working Group
Jose C. Florez, MD, PhD[1, 2]
David Altshuler, MD, PhD[1, 2]
Liana K. Billings, MD[1]
Ling Chen, MS[1]
Maegan Harden, BS[2]
Robert L. Hanson, MD, MPH[3]
William C. Knowler, MD, DrPH[3]
Toni I. Pollin, PhD[4]
Alan R. Shuldiner, MD[4]
Kathleen Jablonski, PhD[5]
Paul W. Franks, PhD, MPhil, MS[6, 7, 8]
Marie-France Hivert, MD[9]

1=Massachusetts General Hospital
2=Broad Institute
3=NIDDK
4=University of Maryland
5=Coordinating Center
6=Lund University, Sweden
7=Umeå University, Sweden
8=Harvard School of Public Health
9=Université de Sherbrooke

* denotes Principal Investigator
** denotes Program Coordinator

©2017 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc17-1116/-/DC1